Study summary · research use only
[Impact of tetrapeptide pancragen on endocrine function of the pancreas in old monkeys]
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
In this study in old female rhesus monkeys, the authors examined the tetrapeptide Pancragen (Lys-Glu-Asp-Trp) on pancreatic endocrine function. The abstract reports that in control conditions old animals showed a reduced glucose 'disappearance' rate and higher insulin and C-peptide peaks (5 and 15 min after glucose injection) than young animals. Pancragen administration (50 microg/animal per day for 10 days, intramuscularly) markedly increased the glucose 'disappearance' rate and normalized plasma insulin and C-peptide dynamics in response to glucose, with the recovering effect partially remaining 3 weeks after discontinuation. The authors describe Pancragen as a promising factor for restoring age-related endocrine dysfunction in primates.
Abstract
Significant increase of the elderly in the demographic structure of a modern society is one of the main reasons for increase in the number of patients with diabetes type 2 and impaired glucose tolerance. The purpose of this research was to study impact of Pancragen (tetrapeptide Lys-Glu-Asp-Trp) on endocrine function of the pancreas of non-human primates, female rhesus monkeys, and to elucidate the possibil- ity of its use for correction age-related dysfunction of pancreatic islet apparatus. In old animals after the glucose administration (standard dose) in control period, a reduced glucose "disappearance" rate and a higher values of insulin and C-peptide peaks (5 and 15 min after the glucose injection) were observed in comparison with young animals in similar experiments. Pancragen administration (50 μg/animal per day during 10 days, intramuscularly) to old monkeys caused markedly increased the glucose "disappear- ance" rate, normalized the plasma insulin and C-peptide dynamics in response to glucose administration. The recovering effect of Pancragen on the function of the pancreas partially remained 3 weeks after discontinuation of the drug. Thus, Pancragen is a promising factor for restoring the age-related endocrine dysfunction of primates.
pepmg summarizes the peer-reviewed literature and links to every source. It sells nothing and ships nothing. Where an FDA label, a peer-reviewed study or a clinical-trial registry entry (labeled trial registry, not peer-reviewed) has published a dose, pepmg reports it with the source named; it gives no personalized recommendations and no administration technique. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.